As part of a multi-year RWE initiative, AMCP Research Institute partnered with IQVIA, payers, pharmaceutical companies, and others to design payer-focused RWE standards that were published in JMCP in September, 2025.
Poster: Continuous Glucose Monitoring
Summary Framework for Improving Precision Oncology in NSCLC Findings From The AMCP Market Insights Program
The expanding use of continuous glucose monitoring (CGM) has been transformative in diabetes care, providing valuable real-time data and insights for diabetes management. CGM coverage in Type 2 diabetes (T2D) has increased, reaching a broader population of patients with diabetes who are recommended for CGM per clinical guidelines.
For more disease state research, view the Market Insights Program.
Related
AMCP’s guidance translates CMS’s expectations for patient centered, evidence informed formulary decisions into practical steps payers can act on today without adding unnecessary burden to P&T workflows.
AMCP launched the metabolic health thought leadership program to empower payers to shift from siloed treatment to holistic, root-cause-focused metabolic health management—redefining roles in benefit design and population outcomes—starting immediately with the new ADA 2026 CGM expansions that are reshaping coverage and access.
Featured News & Resources
See Full CalendarUpcoming Events
AMCP offers a wide variety of educational opportunities, from events and webinars to online training.
